ENTITY – Page 7

About 5% of CBER and CDER Left After FDA Staff Cuts, Analysis Finds

2 weeks ago talkbio0Tagged Biological Factors, CBER, CDER, Drug Approval Process, drug review, layoffs, Staff, Trump administration, United States Food and Drug Administration

FDA layoffs; CBER; CDER; drug review; biologics; staff cuts; Trump administration; drug approval process

GLP-1s May Lower Cancer Risk; Gyre Stock Drops After Hep B Data, Share Offering

2 weeks ago talkbio0Tagged agonists, Cancer Risk, Clinical Data, GLP-1 receptor, Gyre stock, Hepatitis B, Mortality Vital Statistics, Obesity-Related Cancers

GLP-1 receptor agonists; cancer risk; obesity-related cancers; Gyre stock; hepatitis B; clinical data; mortality

Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025

2 weeks ago talkbio0Tagged ASCO, atezolizumab, IMforte trial, Jazz, lurbinectedin, Malignant neoplasm of lung, Overall Survival, Progression-Free Survival, Small cell carcinoma of lung, Tecentriq, Zepzelca

Jazz Pharmaceuticals; Zepzelca; lurbinectedin; lung cancer; small cell lung cancer; Tecentriq; atezolizumab; IMforte trial; overall survival; progression-free survival; ASCO 2025

Sanofi Opens $130M ‘Flagship’ US Office Facility in Morristown, New Jersey

2 weeks ago talkbio0Tagged Corporate, flagship office, Health care facility, innovation, Market, Morristown, sanofi, U.S.

Sanofi; Morristown; flagship office; $130 million; healthcare; innovation; New Jersey; US market; corporate hub

Will Trump’s Tax Bill Cut Medicare by $490 Billion? Not Exactly.

2 weeks ago talkbio0Tagged Beak, Budgets, CBO, healthcare changes, Medicare, reconciliation, Sequestration, Transplant Registry Unified Management Program

Trump tax bill; Medicare cuts; sequestration; budget reconciliation; 2025 healthcare changes; CBO report

Exit Strategy: Biopharma Professionals Consider Opportunities Outside Industry and US

2 weeks ago talkbio0Tagged Biological Science Disciplines, Biopharma, biopharma survey, biotech careers, Drug Industry, employment, Industry, Market, Transition Mutation, trends qualifier, U.S.

biopharma talent; job market trends; industry transition; employment outside US; biopharma survey 2025; life sciences employment; biotech careers; pharmaceutical industry

Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer’s Drug Pipeline

2 weeks ago talkbio0Tagged Acquisition, Agonist, Alzheimer 's disease, Microglia, Neurodegenerative Disorders, Phase 2 Trials, sanofi, TREM2, VG-3927, Vigil Neuroscience

Sanofi; Vigil Neuroscience; acquisition; Alzheimer’s disease; TREM2 agonist; VG-3927; microglia; neurodegenerative disease; Phase 2 trials; biotech deals

HHS: All Branded Drugs Without Generic or Biosimilar Competition Must Abide by MFN Order Across All Markets

2 weeks ago talkbio0Tagged biosimilar competition, branded drugs, CHARGE Syndrome, Country, Drug Industry, drug price, executive order, Generic competition, most-favored, Organisation for Economic Co-Operation and Development

most-favored nation pricing; branded drugs; generic competition; biosimilar competition; HHS; executive order; drug pricing; pharmaceutical industry; OECD countries